Review

Prediction of Anthracycline-Induced Left Ventricular Dysfunction by Cardiac Troponins

Authors: S. Calvin Thigpen, MD, Stephen A. Geraci, MD

Abstract

Evidence suggests prognostic utility of troponin (Tn) serum concentrations for a variety of conditions. We sought to determine whether elevated concentrations early after anthracycline chemotherapy predict the development of left ventricular systolic dysfunction in adult patients with cancer. PubMed/MEDLINE searches identified original reports that assessed cardiac TnI or TnT within 5 days of anthracycline chemotherapy and evaluated left ventricular systolic function after treatment for review. Ten reports qualified for review. Four studies indicated a significant relation between elevated Tn and subsequent left ventricular systolic dysfunction. One study that enrolled patients actively receiving anthracyclines and others who had previously received anthracyclines also demonstrated a significant relation. The remaining five reports identified no such relation. Heterogeneity in experimental methods, sampling times, and handling of confounders was significant between positive and negative studies. The present evidence is insufficient to suggest that Tns are reliable predictors of left ventricular dysfunction in patients with cancer. These data suggest, however, that larger prospective studies using frequent scheduled Tn measurement with adjustment for confounding factors could determine the predictive value of Tns in this setting.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Geraci SA. Canary in the coal mine: cardiac troponins in noncoronary diseases. Am J Med 2012; 125: 527–528.
 
2. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791–809.
 
3. Ewer MS, Benjamin RS. Doxorubicin cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention. In: Ewer MS, Yeh E (eds): Cancer and the Heart. Hamilton, Canada, BC Decker, 2006, 9–32.
 
4. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831–2837.
 
5. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798–804.
 
6. Polena S, Shikara M, Naik S, et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc West Pharmacol Soc 2005; 48: 142–144.
 
7. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47: 2174–2180.
 
8. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029–1033.
 
9. Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008; 97: 318–326.
 
10. Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011; 105: 1663–1668.
 
11. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710–715.
 
12. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–522.
 
13. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248–252.
 
14. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–2754.
 
15. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218–222.